Inhibrx (INBX) Competitors $13.58 +0.33 (+2.49%) Closing price 04:00 PM EasternExtended Trading$13.58 +0.01 (+0.04%) As of 04:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more. Add Compare Share Share Competitors Stock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestSustainabilityTrends INBX vs. BCAX, AVXL, NUVB, RLAY, TYRA, SANA, DNTH, GHRS, VALN, and ABUSShould you be buying Inhibrx stock or one of its competitors? The main competitors of Inhibrx include Bicara Therapeutics (BCAX), Anavex Life Sciences (AVXL), Nuvation Bio (NUVB), Relay Therapeutics (RLAY), Tyra Biosciences (TYRA), Sana Biotechnology (SANA), Dianthus Therapeutics (DNTH), GH Research (GHRS), Valneva (VALN), and Arbutus Biopharma (ABUS). These companies are all part of the "pharmaceutical products" industry. Inhibrx vs. Bicara Therapeutics Anavex Life Sciences Nuvation Bio Relay Therapeutics Tyra Biosciences Sana Biotechnology Dianthus Therapeutics GH Research Valneva Arbutus Biopharma Bicara Therapeutics (NASDAQ:BCAX) and Inhibrx (NASDAQ:INBX) are both small-cap medical companies, but which is the superior business? We will compare the two businesses based on the strength of their dividends, valuation, risk, analyst recommendations, institutional ownership, earnings, community ranking, profitability and media sentiment. Do analysts prefer BCAX or INBX? Bicara Therapeutics currently has a consensus target price of $41.20, indicating a potential upside of 224.41%. Given Bicara Therapeutics' stronger consensus rating and higher possible upside, equities analysts clearly believe Bicara Therapeutics is more favorable than Inhibrx.Company Sell Ratings Hold Ratings Buy Ratings Strong Buy Ratings Rating Score Bicara Therapeutics 0 Sell rating(s) 0 Hold rating(s) 7 Buy rating(s) 1 Strong Buy rating(s) 3.13Inhibrx 0 Sell rating(s) 1 Hold rating(s) 0 Buy rating(s) 0 Strong Buy rating(s) 2.00 Which has preferable earnings and valuation, BCAX or INBX? Bicara Therapeutics has higher earnings, but lower revenue than Inhibrx. CompanyGross RevenuePrice/Sales RatioNet IncomeEarnings Per SharePrice/Earnings RatioBicara TherapeuticsN/AN/AN/AN/AN/AInhibrx$1.57M125.37-$154.96MN/AN/A Does the media prefer BCAX or INBX? In the previous week, Bicara Therapeutics had 1 more articles in the media than Inhibrx. MarketBeat recorded 2 mentions for Bicara Therapeutics and 1 mentions for Inhibrx. Inhibrx's average media sentiment score of 1.87 beat Bicara Therapeutics' score of 1.00 indicating that Inhibrx is being referred to more favorably in the news media. Company Overall Sentiment Bicara Therapeutics Positive Inhibrx Very Positive Do institutionals & insiders have more ownership in BCAX or INBX? 82.5% of Inhibrx shares are owned by institutional investors. 22.2% of Inhibrx shares are owned by insiders. Strong institutional ownership is an indication that hedge funds, endowments and large money managers believe a company is poised for long-term growth. Does the MarketBeat Community believe in BCAX or INBX? Inhibrx received 20 more outperform votes than Bicara Therapeutics when rated by MarketBeat users. However, 100.00% of users gave Bicara Therapeutics an outperform vote while only 58.49% of users gave Inhibrx an outperform vote. CompanyUnderperformOutperformBicara TherapeuticsOutperform Votes11100.00% Underperform VotesNo VotesInhibrxOutperform Votes3158.49% Underperform Votes2241.51% Is BCAX or INBX more profitable? Bicara Therapeutics' return on equity of 0.00% beat Inhibrx's return on equity.Company Net Margins Return on Equity Return on Assets Bicara TherapeuticsN/A N/A N/A Inhibrx N/A -113.74%-80.56% SummaryBicara Therapeutics beats Inhibrx on 8 of the 13 factors compared between the two stocks. Get Inhibrx News Delivered to You Automatically Sign up to receive the latest news and ratings for INBX and its competitors with MarketBeat's FREE daily newsletter. Email Address New MarketBeat Followers Over TimeWhat are MarkeBeat Followers?This chart shows the number of new MarketBeat users adding {thisCompany.Symbol} and its top 5 competitors to their watchlist. Each company is represented with a line over a 90 day period. Skip ChartMedia Sentiment Over TimeWhat is Media Sentiment?This chart shows the average media sentiment of NASDAQ and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.Skip Chart INBX vs. The Competition Export to ExcelMetricInhibrxBiological Products IndustryMedical SectorNASDAQ ExchangeMarket Cap$196.58M$3.08B$5.81B$8.39BDividend YieldN/A1.51%4.75%3.98%P/E RatioN/A28.6624.9519.24Price / Sales125.37403.91375.54110.22Price / CashN/A168.6838.0534.58Price / BookN/A3.487.334.28Net Income-$154.96M-$71.55M$3.18B$247.04M7 Day Performance8.73%-6.66%-4.42%-4.36%1 Month Performance6.76%-9.02%-6.07%-5.60%1 Year Performance-62.74%-22.49%11.42%3.38% Inhibrx Competitors List Export to ExcelCompanyMarketRankShare PriceAnalysts' Price Target1Y Price PerformanceMarket CapRevenueP/E RatioEmployee CountIndicator(s)INBXInhibrx1.1682 of 5 stars$13.58+2.5%N/A-63.6%$196.58M$1.57M0.00166Positive NewsBCAXBicara TherapeuticsN/A$12.98-0.2%$41.20+217.4%N/A$706.37MN/A0.0032High Trading VolumeAVXLAnavex Life Sciences3.7784 of 5 stars$8.26-1.1%$44.00+432.7%+49.8%$702.63MN/A-15.0240NUVBNuvation Bio1.6325 of 5 stars$2.09-5.7%$8.20+293.3%-12.3%$701.75MN/A-0.9660Analyst ForecastNews CoverageGap UpRLAYRelay Therapeutics3.1358 of 5 stars$3.88-1.0%$20.50+428.4%-66.2%$649.43M$25.55M-1.49330Earnings ReportTYRATyra Biosciences1.7764 of 5 stars$12.82-2.7%$30.50+137.9%-41.2%$648.69MN/A-7.9620Short Interest ↑SANASana Biotechnology2.9019 of 5 stars$2.88-4.3%$14.25+394.8%-76.8%$643.02MN/A-2.06380DNTHDianthus Therapeutics1.8482 of 5 stars$21.60-8.7%$46.83+116.8%-16.1%$639.30M$5.37M-8.6480GHRSGH Research2.0271 of 5 stars$12.21-2.4%$30.25+147.7%+19.2%$635.29MN/A-15.4610Earnings ReportShort Interest ↑VALNValneva2.862 of 5 stars$7.81+5.0%$17.00+117.7%-4.5%$634.64M$165.52M-60.08700Analyst ForecastGap UpABUSArbutus Biopharma2.1735 of 5 stars$3.34-2.3%$5.50+64.7%+23.7%$632.90M$6.74M-7.7790News Coverage Related Companies and Tools Related Companies Bicara Therapeutics Alternatives Anavex Life Sciences Alternatives Nuvation Bio Alternatives Relay Therapeutics Alternatives Tyra Biosciences Alternatives Sana Biotechnology Alternatives Dianthus Therapeutics Alternatives GH Research Alternatives Valneva Alternatives Arbutus Biopharma Alternatives Top 10 Stock Comparisons Bank Stocks Artificial Intelligence Stocks Toy Stocks Growth Stocks Airline Stocks Chinese Stocks EV Charging Stocks Defense Stocks Lithium Stocks Pharmaceutical Stocks This page (NASDAQ:INBX) was last updated on 3/3/2025 by MarketBeat.com Staff From Our PartnersDOGE Social Security bombshell?Elon Musk just dropped another bombshell... He revealed his DOGE organization has been taking aim at Social...Altimetry | SponsoredElon Musk Wants to Audit Fort Knox—What It Means for Your RetirementYou can take advantage of the coming tariff-fueled gold melt-up right inside your IRA or 401(k) – 100% TAX-FRE...Colonial Metals | SponsoredURGENT: This Altcoin Opportunity Won’t Wait – Act NowCrypto has officially entered the "banana zone" – that wild phase where prices can 1000x in days. It happen...Crypto Swap Profits | SponsoredThis Crypto Is Set to Explode in FebruaryIt's a groundbreaking opportunity that could be poised for extraordinary gains. The catalyst behind this su...Crypto 101 Media | SponsoredThe Deep State Surveillance Plot To Sabotage President TrumpThere's a Trump approved IRS-loophole which allows you to steer clear of government overreach and move your re...American Hartford Gold | SponsoredTrump’s Victory Could Spark Major Gains for Gold – Don’t Miss Out This "Patriot's Tax Shield" lets you defend your wealth with real, solid gold. Our exclusive, free wealth pr...American Alternative | SponsoredCollect $7k per month from Tesla’s SECRET dividendTesla doesn't pay a traditional dividend.... But I just discovered a secret backdoor to collect a secret 69...Investors Alley | Sponsored$2 Trillion Disappears Because of Fed's Secretive New Move$2 trillion has disappeared from the US government's books. The reason why is a new, secretive move being c...Stansberry Research | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Inhibrx, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Inhibrx With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
Free INBX Stock Alerts